C A Rodriguez1, M B Brooks1, L Guglielmetti2,3,4, C Hewison2, M F Jachym5, E Lessem6, F Varaine2, C D Mitnick1. 1. Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA. 2. Médecins Sans Frontières, Paris, France. 3. Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Assistance publique Hopitaux de Paris, Paris, France. 4. Team E13 (Bactériologie), Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, Université Pierre et Marie Curie, Université Paris 06, Centre de Recherche 7, Institut national de la Santé et de la Recherche médicale Unité 1135, Paris, France. 5. Sanatorium, Centre Hospitalier de Bligny, Briissous-Forges, France. 6. Treatment Action Group, New York, New York, USA.
Abstract
SETTING: Phase II trials for bedaquiline (BDQ) and delamanid (DLM) were completed by 2011 and the drugs were approved by stringent regulatory authorities for the treatment of multidrug-resistant tuberculosis (MDR-TB) between 2012 and 2014. Manufacturers established 'early access' mechanisms to provide drugs before local registration. OBJECTIVE: To inform improvements in early access, we explored experiences of providers and advocates in accessing BDQ and DLM before the end of 2015 using a mixed-methods design. DESIGN: We examined barriers and facilitators to early access through an electronic survey. Barriers and facilitators were classified as occurring at the manufacturer- or country-level. We identified themes using inductive content analysis and illustrated themes through case studies. RESULTS: We analysed 41 survey responses from 36 respondents reporting on 22 countries; early access was attempted in 30 (73%) survey responses. Eligibility restrictions (11/30, 37%) and complicated and slow processes (8/30, 27%) were manufacturer-level barriers; access to companion drugs (10, 33%) and importation difficulties (4, 13%) were country-level barriers. Previous experience with manufacturer (3/30, 10%) and country processes (2/30, 7%) facilitated access. Eight case studies show the human impact of barriers and facilitators. CONCLUSION: Manufacturers and countries should develop transparent processes to permit early access, particularly for diseases that largely affect the poor, such as MDR-TB. Developers should plan for this need and rapidly register drugs with proven benefit, prioritizing high-burden settings.
SETTING: Phase II trials for bedaquiline (BDQ) and delamanid (DLM) were completed by 2011 and the drugs were approved by stringent regulatory authorities for the treatment of multidrug-resistant tuberculosis (MDR-TB) between 2012 and 2014. Manufacturers established 'early access' mechanisms to provide drugs before local registration. OBJECTIVE: To inform improvements in early access, we explored experiences of providers and advocates in accessing BDQ and DLM before the end of 2015 using a mixed-methods design. DESIGN: We examined barriers and facilitators to early access through an electronic survey. Barriers and facilitators were classified as occurring at the manufacturer- or country-level. We identified themes using inductive content analysis and illustrated themes through case studies. RESULTS: We analysed 41 survey responses from 36 respondents reporting on 22 countries; early access was attempted in 30 (73%) survey responses. Eligibility restrictions (11/30, 37%) and complicated and slow processes (8/30, 27%) were manufacturer-level barriers; access to companion drugs (10, 33%) and importation difficulties (4, 13%) were country-level barriers. Previous experience with manufacturer (3/30, 10%) and country processes (2/30, 7%) facilitated access. Eight case studies show the human impact of barriers and facilitators. CONCLUSION: Manufacturers and countries should develop transparent processes to permit early access, particularly for diseases that largely affect the poor, such as MDR-TB. Developers should plan for this need and rapidly register drugs with proven benefit, prioritizing high-burden settings.
Entities:
Keywords:
compassionate use; drug-resistant tuberculosis; early access; expanded access
Authors: Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley Journal: N Engl J Med Date: 2009-06-04 Impact factor: 91.245
Authors: Andreas H Diacon; Alexander Pym; Martin P Grobusch; Jorge M de los Rios; Eduardo Gotuzzo; Irina Vasilyeva; Vaira Leimane; Koen Andries; Nyasha Bakare; Tine De Marez; Myriam Haxaire-Theeuwes; Nacer Lounis; Paul Meyvisch; Els De Paepe; Rolf P G van Heeswijk; Brian Dannemann Journal: N Engl J Med Date: 2014-08-21 Impact factor: 91.245
Authors: A H Diacon; P R Donald; A Pym; M Grobusch; R F Patientia; R Mahanyele; N Bantubani; R Narasimooloo; T De Marez; R van Heeswijk; N Lounis; P Meyvisch; K Andries; D F McNeeley Journal: Antimicrob Agents Chemother Date: 2012-03-05 Impact factor: 5.191
Authors: Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Jan-William C Alffenaar; Holly A Anger; Jose A Caminero; Paolo Castiglia; Saverio De Lorenzo; Giovanni Ferrara; Won-Jung Koh; Giesela F Schecter; Tae S Shim; Rupak Singla; Alena Skrahina; Antonio Spanevello; Zarir F Udwadia; Miquel Villar; Elisabetta Zampogna; Jean-Pierre Zellweger; Alimuddin Zumla; Giovanni Battista Migliori Journal: Eur Respir J Date: 2012-04-10 Impact factor: 16.671
Authors: Maria Tarcela Gler; Vija Skripconoka; Epifanio Sanchez-Garavito; Heping Xiao; Jose L Cabrera-Rivero; Dante E Vargas-Vasquez; Mengqiu Gao; Mohamed Awad; Seung-Kyu Park; Tae Sun Shim; Gee Young Suh; Manfred Danilovits; Hideo Ogata; Anu Kurve; Joon Chang; Katsuhiro Suzuki; Thelma Tupasi; Won-Jung Koh; Barbara Seaworth; Lawrence J Geiter; Charles D Wells Journal: N Engl J Med Date: 2012-06-07 Impact factor: 91.245
Authors: G B Migliori; G Sotgiu; N R Gandhi; D Falzon; K DeRiemer; R Centis; M G Hollm-Delgado; D Palmero; C Pérez-Guzmán; M H Vargas; L D'Ambrosio; A Spanevello; M Bauer; E D Chan; H S Schaaf; S Keshavjee; T H Holtz; D Menzies Journal: Eur Respir J Date: 2012-10-11 Impact factor: 16.671
Authors: C R Horsburgh; M Haxaire-Theeuwes; C Lienhardt; C Wingfield; D McNeeley; L Pyne-Mercier; S Keshavjee; F Varaine Journal: Int J Tuberc Lung Dis Date: 2012-12-04 Impact factor: 2.373
Authors: Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies Journal: Eur Respir J Date: 2012-10-25 Impact factor: 16.671